Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025
12 Fevereiro 2025 - 6:05PM
Business Wire
Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that the
Company will provide a corporate update and report financial
results for the fourth quarter and full year ended December 31,
2024, on February 26, 2025. The Company will host a conference call
at 1:30 p.m. PT / 4:30 p.m. ET on February 26, 2025.
The corporate update and financial results will be provided via
a press release after market close and will be accessible on the
News page in the Investors section of the Vir Biotechnology
website. Participants may access the conference call via webcast on
the Events & Presentations page of the Vir Biotechnology
website or via phone by dialing the U.S. toll free number +1 (888)
800-8770 or international number +1 (646) 307-1953, Conference ID:
7568777. A recorded version of the conference call will be
available approximately two hours after the completion of the event
and will be archived for 30 days.
About Vir Biotechnology, Inc.
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical
company focused on powering the immune system to transform lives by
discovering and developing medicines for serious infectious
diseases and cancer. Its clinical-stage portfolio includes
infectious disease programs for chronic hepatitis delta and chronic
hepatitis B infections and multiple dual-masked T-cell engagers
across validated targets in solid tumor indications. Vir
Biotechnology also has a preclinical portfolio of programs across a
range of infectious diseases and oncologic malignancies. Vir
Biotechnology routinely posts information that may be important to
investors on its website.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20250212148653/en/
Media Arran Attridge Senior Vice President, Corporate
Communications aattridge@vir.bio
Investors Richard Lepke Senior Director, Investor
Relations rlepke@vir.bio
Vir Biotechnology (NASDAQ:VIR)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025
Vir Biotechnology (NASDAQ:VIR)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025